NASDAQ$ALNY
Alnylam Pharmaceuticals Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
ALNY Q3 2024 — $420K revenue
United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of opera. Alnylam Pharmaceuticals Inc reported Q3 2024 results. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $420K.
- Operating income: $77K.
- Filed on Form 10-Q (accession 0001178670-24-000053).
Headline financials
Revenue & EPS history
Alnylam · Revenue · Quarterly
$501M
Revenue by segment
Alnylam · $313M total across 4 segments · Q3 2023
- AMVUTTRA$149M+489.3%47.5%
- ONPATTRO$81.6M-43.7%26.1%
- GIVLAARI$54.1M+18.6%17.3%
- OXLUMO$28.7M+74.9%9.2%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-1.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.5%
Avg return
30 days after
48%
31 / 65 earnings
Positive
+15.4%
Q2 2025
Best reaction
-16.9%
Q2 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | -0.0% | +0.2% | |
| Q4 2025 | -4.3% | +3.2% | -2.8% | |
| Q3 2025 | -6.7% | -12.1% | -6.3% | |
| Q2 2025 | +15.4% | +23.3% | +31.4% | |
| Q1 2025 | -3.1% | +2.5% | +15.7% | |
| Q4 2024 | -0.4% | -6.0% | -9.1% | |
| Q3 2024 | -2.7% | -5.8% | -10.1% | |
| Q2 2024 | +14.6% | +10.6% | +10.6% | |
| Q1 2024 | +1.6% | +2.9% | -1.0% | |
| Q4 2023 | -10.4% | -8.8% | -9.1% | |
| Q3 2023 | +6.6% | +8.4% | +9.2% | |
| Q2 2023 | -0.8% | -1.2% | +7.6% | |
| Q1 2023 | +6.3% | +4.2% | -2.9% | |
| Q4 2022 | -5.6% | -4.8% | -5.5% | |
| Q3 2022 | +1.7% | +6.0% | +5.8% | |
| Q2 2022 | +0.0% | +0.0% | +48.6% | |
| Q1 2022 | -13.9% | -7.8% | -17.5% | |
| Q4 2021 | -0.4% | +1.3% | +2.4% | |
| Q3 2021 | -16.5% | -12.3% | -1.4% | |
| Q2 2021 | +3.1% | +9.7% | +12.5% | |
| Q1 2021 | -2.0% | -8.3% | -1.1% | |
| Q4 2020 | -3.8% | -6.3% | -13.4% | |
| Q3 2020 | -6.3% | -10.4% | -7.1% | |
| Q2 2020 | -4.6% | -9.2% | -18.4% | |
| Q1 2020 | +0.2% | +0.8% | -9.7% | |
| Q4 2019 | +3.2% | +6.5% | -6.7% | |
| Q3 2019 | +4.3% | +5.5% | +34.2% | |
| Q2 2019 | +12.7% | +13.1% | +16.4% | |
| Q1 2019 | -7.6% | -17.1% | -24.4% | |
| Q4 2018 | -5.0% | +2.5% | +1.8% | |
| Q3 2018 | -15.3% | -21.3% | -13.8% | |
| Q2 2018 | -3.0% | -0.6% | +29.8% | |
| Q1 2018 | +2.6% | +6.8% | +11.8% | |
| Q4 2017 | -5.1% | -2.3% | +9.0% | |
| Q3 2017 | +1.4% | +7.3% | -1.4% | |
| Q2 2017 | -6.8% | -2.2% | -9.5% | |
| Q1 2017 | -4.1% | +1.5% | +31.2% | |
| Q4 2016 | +11.1% | +12.7% | +25.4% | |
| Q3 2016 | -15.1% | -2.0% | +12.4% | |
| Q2 2016 | +9.9% | +7.1% | -3.1% | |
| Q1 2016 | -9.3% | — | — | |
| Q4 2015 | +4.5% | — | — | |
| Q3 2015 | +5.6% | — | — | |
| Q2 2015 | -16.9% | — | — | |
| Q1 2015 | +6.7% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | +3.2% | — | — | |
| Q2 2014 | +1.5% | — | — | |
| Q1 2014 | +5.3% | — | — | |
| Q4 2013 | -2.1% | — | — | |
| Q3 2013 | -11.2% | — | — | |
| Q2 2013 | +3.7% | — | — | |
| Q1 2013 | +3.5% | — | — | |
| Q4 2012 | -0.7% | — | — | |
| Q3 2012 | +0.7% | — | — | |
| Q2 2012 | -1.5% | — | — | |
| Q1 2012 | -9.0% | — | — | |
| Q4 2011 | -9.6% | — | — | |
| Q3 2011 | +1.5% | — | — | |
| Q2 2011 | -14.9% | — | — | |
| Q1 2011 | +2.3% | — | — | |
| Q4 2010 | +13.2% | — | — | |
| Q3 2010 | +2.4% | — | — | |
| Q2 2010 | -0.9% | — | — | |
| Q1 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro